Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SEINRLF 52 EV-to-EBIT is -5.55 as of Aug. 01, 2026. GuruFocus rates INRLF with a GF Score™ of 52/100 and a GF Value™ of $2.73 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 382 Biotechnology companies, Valneva SE ranks worse than 261779.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Valneva SE's Enterprise Value for the quarter that ended in Mar. 2026 was $664.4 Mil.
Valneva SE's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE EV-to-EBIT Related Terms
Valneva SE EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Valneva SE's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Valneva SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Valneva SE's EV-to-EBIT falls into.
Valneva SE's current Enterprise Value is $625.6 Mil.
Valneva SE's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (INRLF) has a EV-to-EBIT of -5.55 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Valneva SE and its competitors. According to the industry distribution chart, Valneva SE ranks #999999 out of 382 companies in the Biotechnology industry.
Is Valneva SE's EV-to-EBIT too high?
Valneva SE's current EV-to-EBIT is -5.55. Based on the distribution chart, Valneva SE ranks #999999 out of 382 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valneva SE has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #999999 out of 382 companies for EV-to-EBIT. This places Valneva SE in the lower half of its industry. The industry median EV-to-EBIT is 12.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.56, based on 382 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Valneva SE and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current EV-to-EBIT is -5.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.73, compared to a current price of $2.43 — trading 11.2% below its estimated fair value. The current EV-to-EBIT is -5.55. Valneva SE's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Valneva SE (INRLF), the current EV-to-EBIT is -5.55 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (INRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of $2.43 is trading 11.2% below its estimated GF Value™ of $2.73.
GuruFocus considers Valneva SE to be Modestly Undervalued.
Key valuation signals for INRLF:
EV-to-EBIT: -5.55
GF Value™: $2.73 vs. price of $2.43 (11.2% below fair value)
No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
52GF Score
Get the complete analysis for INRLF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INRLF has been successfully added to your 
